Date:9/27/2007

are based on current assumptions and expectations and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. These risks include the ability of Flextronics and Solectron to satisfy the conditions to closing. Additional information concerning these and other risks is described under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Flextronics's reports on Form 10-K, 10-Q and 8-K that Flextronics has filed with the U.S. Securities and Exchange Commission ("SEC") and under "Cautionary Statement Regarding Forward Looking Information" and "Risk Factors" included in the Joint Proxy Statement/Prospectus which forms a part of Flextronics's registration statement on Form S-4/A, filed by Flextronics with the SEC on August 7, 2007. The forward-looking statements in this communication are based on current expectations and Flextronics assumes no obligation to update these forward- looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements.

'/>"/>

SOURCE Flextronics International Ltd. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. NEW ROBOTIC SURGERY ARM APPROVED BY FDA
2. Abortion Pill approved by FDA
3. Another injectable contraceptive Pill approved by FDA
4. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
5. New FDA Approved Drug To Treat Migraine
6. Lose Weight With New Wonder Slimming FDA approved Prescription Drug
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. FDA approves Phase 0 trial which tests experimental drugs on humans
9. FDA Approves Contraceptive Ring
10. FDA approves new device to treat womens bleeding disorder
11. FDA Approves New HIV Drug, Viread